Sarcopenia and Aging: How Muscle Loss Drives Broader Decline and What Stops It

Sarcopenia is now recognized as a formal muscle disorder by the European Working Group on Sarcopenia in Older People (EWGSOP2), defined by progressive, generalized loss of skeletal muscle mass and quality. Its prevalence ranges from 8–36% in adults under 60 and 10–27% in those over 60, with projections rising as global populations age. Beyond physical frailty, sarcopenia imposes substantial healthcare costs and deepens social inequalities—making effective intervention strategies an urgent priority.

At the cellular level, three interlocking mechanisms drive sarcopenia. First, chronic low-grade inflammation elevates circulating CRP, IL-6, TNF-α, and IL-1β, promoting anabolic resistance, protein degradation via the ubiquitin-proteasome system, and satellite cell suppression. The NLRP3 inflammasome and pyroptosis pathway have emerged as specific molecular nodes, demonstrated in animal denervation models, though direct human evidence remains limited. Second, oxidative stress—an age-related imbalance between reactive oxygen species production and antioxidant capacity—causes lipid peroxidation, protein carbonylation, and DNA damage in skeletal muscle, impairing myoblast regeneration and satellite cell function. Mitochondria are the primary ROS targets and lack robust repair mechanisms, making them especially vulnerable. Third, mitochondrial dysfunction arises from disrupted biogenesis-to-mitophagy balance, altering cellular bioenergetics and accelerating muscle loss. Physical inactivity compounds the pro-oxidant environment, while exercise—though unable to fully reverse mitochondrial aging—meaningfully attenuates dysfunction.

Sarcopenia does not operate in isolation. Its pathophysiology overlaps substantially with type 2 diabetes (shared insulin resistance and inflammatory pathways), obesity (sarcopenic obesity), and neurodegenerative diseases. The muscle-brain axis is highlighted as a critical frontier: muscle mass may serve as a biomarker in dementia prevention, and sarcopenia is present in more than 50% of Parkinson's disease patients, correlating with worse motor outcomes, more falls, and poorer non-motor symptoms. Declining androgen levels with aging further accelerate muscle catabolism and reduce anti-inflammatory protection, establishing hormonal factors as an additional therapeutic target.

On the intervention side, the review synthesizes evidence for multicomponent strategies. Resistance exercise training is the cornerstone, consistently improving muscle strength and function while reducing pro-inflammatory cytokines. Nutritional approaches—particularly high-protein diets (emphasizing leucine for mTOR-mediated anabolic signaling), vitamin D supplementation (supporting muscle protein synthesis and immune modulation), and omega-3 fatty acids (attenuating inflammation and anabolic resistance)—demonstrate additive benefits when combined with exercise. Emerging evidence on probiotics suggests they may improve inflammatory status and muscle function by modulating the gut-muscle axis, though this area requires further randomized trial data. The authors emphasize that no single intervention is sufficient; integrated, personalized multicomponent protocols yield the most consistent results across outcomes.

Key caveats include the review's reliance on heterogeneous study designs, many of which involve animal models or small human trials. Direct mechanistic evidence for some pathways (e.g., pyroptosis in human sarcopenia) remains sparse. Optimal dosing and duration for supplementation protocols are not yet standardized, and applicability across diverse populations and sarcopenia subtypes warrants further investigation.